ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Mar 31, 2017
Sanofi: The First Victim in the Great Insulin Price War
The steady growth expected from Diabetes products has come to an abrupt halt. Is Sanofi adequately prepared to replace the revenue loss of its top-selling product?
Mar 30, 2017
Who’s Driving Who: The Future of the Automakers
Image Source: HimmelrichPR. Let’s dig into some recent developments surrounding the auto market, and how technological and strategic innovation could reshape the future of the space.
Mar 30, 2017
Analyzing Amgen's Sudden Fall
Amgen’s share price has run up in anticipation of positive results from its key pipeline product Repatha. Now that the results are out, doubt has crept in concerning the overall viability of the product. Let’s examine.
Mar 16, 2017
Buffalo Wild Wings: It’s Time to Start Delivering?
Best Ideas Newsletter portfolio holding Buffalo Wild Wings is battling a challenging operating environment. Management is searching for ways to shore up performance, but some shareholders are getting antsy. Is a BWLD-WING deal in the cards?
Mar 13, 2017
Dividend Increases/Decreases for the Week Ending March 10
Let's take a look at companies raising/lowering their dividends this week.
Mar 11, 2017
Celgene: A Hemeoncology Powerhouse
Let’s walk through the investment merits of one of the market darlings in biotech.
Mar 10, 2017
Priceline Delivers on Bookings Strength, Free Cash Flow Growth
Best Ideas Newsletter portfolio holding Priceline finished 2016 on a high note. Let’s take a quick look at its fourth-quarter report.
Mar 6, 2017
Dividend Increases/Decreases for the Week Ending March 3
Let's take a look at companies raising/lowering their dividend this week.
Mar 2, 2017
Dow 21,000+; Forward P/E on S&P 500 ~18!!!
To say that the broader equity market is “extended” is an understatement.
Feb 27, 2017
Valuentum's Brian Nelson to Present at CFA Society of Houston
Valuentum's Brian Nelson has been invited to speak at the CFA Society of Houston in March of this year! Mr. Nelson will walk through his experiences in valuation and financial statement analysis within the stock selection process to help portfolio managers learn how to optimize the strength and resilience of client portfolios--those either built for capital appreciation or income, or both.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.